Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3295668 in platinum-sensitive extensive-stage SCLC
NCT03898791Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 1, open-label trial of LY3295668 in small cell lung cancer (SCLC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with Dose Reductions, Objective Response Rate up to 20 months and 2 more. Started Jul 2019; status: completed.
02
Drugs
LY3295668
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03898791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898791.